派姆单抗联合化疗治疗晚期子宫内膜癌

IF 4.3 4区医学 Q1 OBSTETRICS & GYNECOLOGY

Obstetrical & Gynecological Survey Pub Date : 2023-07-01 DOI:10.1097/01.ogx.0000947152.26004.f9

Ramez N. Eskander, Michael W. Sill, Lindsey Beffa, Richard G. Moore, Joanie M. Hope, Fernanda B. Musa, Robert Mannel, Mark S. Shahin, Guilherme H. Cantuaria, Eugenia Girda, Cara Mathews, Juraj Kavecansky, Charles A. Leath, Lilian T. Gien, Emily M. Hinchcliff, Shashikant B. Lele, Lisa M. Landrum, Floor Backes, Roisin E. O'Cearbhaill, Tareq Al Baghdadi, Emily K. Hill, Premal H. Thaker, Veena S. John, Stephen Welch, Amanda N. Fader, Matthew A. Powell, Carol Aghajanian

{"title":"派姆单抗联合化疗治疗晚期子宫内膜癌","authors":"Ramez N. Eskander, Michael W. Sill, Lindsey Beffa, Richard G. Moore, Joanie M. Hope, Fernanda B. Musa, Robert Mannel, Mark S. Shahin, Guilherme H. Cantuaria, Eugenia Girda, Cara Mathews, Juraj Kavecansky, Charles A. Leath, Lilian T. Gien, Emily M. Hinchcliff, Shashikant B. Lele, Lisa M. Landrum, Floor Backes, Roisin E. O'Cearbhaill, Tareq Al Baghdadi, Emily K. Hill, Premal H. Thaker, Veena S. John, Stephen Welch, Amanda N. Fader, Matthew A. Powell, Carol Aghajanian","doi":"10.1097/01.ogx.0000947152.26004.f9","DOIUrl":null,"url":null,"abstract":"(Abstracted from N Engl J Med 2023;388(23):2159–2170) Endometrial cancer is one of the only cancer types for which both incidence and mortality are rising, and survival has not improved during the past 4 decades. First-line treatment for advanced or recurrent endometrial cancer typically involves paclitaxel plus carboplatin.","PeriodicalId":19409,"journal":{"name":"Obstetrical & Gynecological Survey","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer\",\"authors\":\"Ramez N. Eskander, Michael W. Sill, Lindsey Beffa, Richard G. Moore, Joanie M. Hope, Fernanda B. Musa, Robert Mannel, Mark S. Shahin, Guilherme H. Cantuaria, Eugenia Girda, Cara Mathews, Juraj Kavecansky, Charles A. Leath, Lilian T. Gien, Emily M. Hinchcliff, Shashikant B. Lele, Lisa M. Landrum, Floor Backes, Roisin E. O'Cearbhaill, Tareq Al Baghdadi, Emily K. Hill, Premal H. Thaker, Veena S. John, Stephen Welch, Amanda N. Fader, Matthew A. Powell, Carol Aghajanian\",\"doi\":\"10.1097/01.ogx.0000947152.26004.f9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"(Abstracted from N Engl J Med 2023;388(23):2159–2170) Endometrial cancer is one of the only cancer types for which both incidence and mortality are rising, and survival has not improved during the past 4 decades. First-line treatment for advanced or recurrent endometrial cancer typically involves paclitaxel plus carboplatin.\",\"PeriodicalId\":19409,\"journal\":{\"name\":\"Obstetrical & Gynecological Survey\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obstetrical & Gynecological Survey\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/01.ogx.0000947152.26004.f9\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrical & Gynecological Survey","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.ogx.0000947152.26004.f9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 1

摘要

(摘要/ abstract)子宫内膜癌是近40年来发病率和死亡率均在上升的癌症类型之一，其生存率并没有提高。晚期或复发子宫内膜癌的一线治疗通常包括紫杉醇加卡铂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer

(Abstracted from N Engl J Med 2023;388(23):2159–2170) Endometrial cancer is one of the only cancer types for which both incidence and mortality are rising, and survival has not improved during the past 4 decades. First-line treatment for advanced or recurrent endometrial cancer typically involves paclitaxel plus carboplatin.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Obstetrical & Gynecological Survey 医学-妇产科学

CiteScore

2.70

自引率

3.20%

发文量

245

审稿时长

>12 weeks

期刊介绍： Each monthly issue of Obstetrical & Gynecological Survey presents summaries of the most timely and clinically relevant research being published worldwide. These concise, easy-to-read summaries provide expert insight into how to apply the latest research to patient care. The accompanying editorial commentary puts the studies into perspective and supplies authoritative guidance. The result is a valuable, time-saving resource for busy clinicians.